NSC-87877|cas:56990-57-9|西域试剂

NSC-87877,98.78%

产品编号：Bellancom-18756| CAS NO：56990-57-9| 分子式：C₁₉H₁₃N₃O₇S₂| 分子量：459.45

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-18756	￥650.00	杭州北京（现货）
Bellancom-18756	￥1050.00	杭州北京（现货）
Bellancom-18756	￥2150.00	杭州北京（现货）
Bellancom-18756	￥3500.00	杭州北京（现货）
Bellancom-18756	￥5800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

NSC-87877

产品介绍

NSC-87877 是一种有效的Shp2 和Shp1 蛋白质酪氨酸磷酸酶抑制剂，IC₅₀ 值分别为0.318 μM 和0.355 μM。NSC-87877还抑制双特异性磷酸酶26 (DUSP26)。

生物活性

NSC-87877 is a potent inhibitor of Shp2 and Shp1 protein tyrosine phosphatases (SH-PTP2 and SH-PTP1), with IC₅₀ values of 0.318 μM, 0.355 μM shp2 and shp1, respectively. NSC-87877 also inhibits dual-specificity phosphatase 26 (DUSP26).

体外研究

NSC-87877 (0-0.5 μM, 5 days) inhibits DUSP26 function in NB cell lines.
NSC-87877 (0-0.5 μM, 5 days) results in increased p53 phosphorylation (Ser37 and Ser46) and activation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	p53 wild-type neuroblastoma (NB) cell lines.
Concentration:	0, 0.25, 0.5 μM.
Incubation Time:	5 dsys.
Result:	Resulted in increased p53 phosphorylation (Ser37 and Ser46) and activation, increased activation of downstream p38 effector proteins (heat shock protein 27 (HSP27) and MAP kinase-activated protein kinase 2 (MAPKAPK2)) and poly ADP ribose polymerase/caspase-3 cleavage. Inhibited DUSP26 function in NB cell lines. Resulted in apoptosis in many cell lines at varying IC₅₀ levels of 1.84 μM (IMR32), 6.35 μM (SK-N-SH), 8.69 μM (NB-19), 12.6 μM (SMS-KCN), 15.7 μM (SH-SY5Y), 15.8 μM (JF) and 19.0 μM (CHLA-225), respectively.

体内研究
(In Vivo)

NSC-87877 (30 mg/kg, IP once daily for 15 days) possesses excellent anti- neuroblastoma activity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intrarenal neuroblastoma (NB) tumor mouse model in female nude mice.
Dosage:	30 mg/kg.
Administration:	IP once daily for 15 days.
Result:	Significantly inhibited NB tumor growth.

体内研究

NSC-87877 (30 mg/kg, IP once daily for 15 days) possesses excellent anti- neuroblastoma activity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intrarenal neuroblastoma (NB) tumor mouse model in female nude mice.
Dosage:	30 mg/kg.
Administration:	IP once daily for 15 days.
Result:	Significantly inhibited NB tumor growth.

体内研究

NSC-87877 (30 mg/kg, IP once daily for 15 days) possesses excellent anti- neuroblastoma activity.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Intrarenal neuroblastoma (NB) tumor mouse model in female nude mice.
Dosage:	30 mg/kg.
Administration:	IP once daily for 15 days.
Result:	Significantly inhibited NB tumor growth.

性状

Solid

溶解性数据

In Vitro:

H₂O : 23.81 mg/mL (51.82 mM; ultrasonic and warming and heat to 60°C)

DMSO : 16.67 mg/mL (36.28 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1765 mL	10.8826 mL	21.7652 mL
5 mM	0.4353 mL	2.1765 mL	4.3530 mL
10 mM	0.2177 mL	1.0883 mL	2.1765 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： PBS
Solubility: 3.33 mg/mL (7.25 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (4.53 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.53 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 1.67 mg/mL (3.63 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (3.63 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液